Matthew Dukewich
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Matthew Dukewich has a total of 42 co-authors. Here are the top co-authors by number of shared publications:
- Jennifer L. Dodge
Division of Gastroenterology and Liver Diseases, University of Southern California Keck School of Medicine, Los Angeles, CA, USA; Department of Population and Public Health Sciences, University of Southern California Keck School of Medicine, Los Angeles, CA, USA
4 shared publications - Norah Terrault
Division of Gastrointestinal and Liver Diseases, Department of Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California, USA
4 shared publications - Brian P. Lee
Division of Gastrointestinal and Liver Diseases, Department of Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California, USA
2 shared publications - Ethan M. Weinberg
Division of Gastroenterology and Hepatology, Department of Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA
2 shared publications Liyun Yuan
Division of Gastrointestinal and Liver Diseases, University of Southern California, Los Angeles, CA, United States
2 shared publications- Michael Ronan Lucey
Division of Gastroenterology and Hepatology, Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI 53705, USA
2 shared publications
Latest Publications
- Top Cited PapersOpen Access
- 11 February 2026
- Published by Elsevier in Journal of Hepatology
- Vol. 85 (1) , 37-47
Longitudinal changes in cardiometabolic risk factors are associated with changes in liver stiffness in adults with MASLD
- 11 February 2026
- Published by Elsevier in Journal of Hepatology
- Vol. 85 (1) , 37-47
Top Cited PapersOpen AccessLongitudinal changes in cardiometabolic risk factors are associated with changes in liver stiffness in adults with MASLD
- 29 September 2025
- Published by Wolters Kluwer Health in Liver Transplantation
- Vol. 32 (5) , 737-747
Reproductive health in the liver transplant recipient
Rates of liver transplantation (LT) are rising in young adults, including among reproductive-aged females. While pregnancy outcomes are overall favorable, these pregnancies are at higher risk and warrant careful planning and immunosuppression management. Transplant recipients value receiving reproductive health counseling from their transplant team; thus, provider knowledge surrounding pre-conception through postpartum management is key to optimizing obstetric and graft outcomes. A critical role of transplant providers lies in reproductive counseling to ascertain whether patients are sexually active, whether they hope to avoid pregnancy, and/or desire future pregnancy planning. This review, therefore, highlights the key clinical considerations with practical guidance for counseling and management of reproductive health in LT recipients.
- 29 September 2025
- Published by Wolters Kluwer Health in Liver Transplantation
- Vol. 32 (5) , 737-747
Reproductive health in the liver transplant recipient
Rates of liver transplantation (LT) are rising in young adults, including among reproductive-aged females. While pregnancy outcomes are overall favorable, these pregnancies are at higher risk and warrant careful planning and immunosuppression management. Transplant recipients value receiving reproductive health counseling from their transplant team; thus, provider knowledge surrounding pre-conception through postpartum management is key to optimizing obstetric and graft outcomes. A critical role of transplant providers lies in reproductive counseling to ascertain whether patients are sexually active, whether they hope to avoid pregnancy, and/or desire future pregnancy planning. This review, therefore, highlights the key clinical considerations with practical guidance for counseling and management of reproductive health in LT recipients.
- 17 September 2025
- Published by Elsevier in Clinical Gastroenterology and Hepatology
- Vol. 24 (5) , 1344-1353
Differential Effects of Cardiometabolic Risk Factors on All-Cause Mortality in United States Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
- 17 September 2025
- Published by Elsevier in Clinical Gastroenterology and Hepatology
- Vol. 24 (5) , 1344-1353
Differential Effects of Cardiometabolic Risk Factors on All-Cause Mortality in United States Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
- 24 July 2025
- Published by Wolters Kluwer Health in Liver Transplantation
- Vol. 31 (11) , 1313-1315
Fellows’ Corner
An abstract is unavailable. This article is available as a PDF only.
- 24 July 2025
- Published by Wolters Kluwer Health in Liver Transplantation
- Vol. 31 (11) , 1313-1315
Fellows’ Corner
An abstract is unavailable. This article is available as a PDF only.
- 22 April 2025
- Published by Wolters Kluwer Health in Liver Transplantation
- Vol. 31 (8) , 973-974
Fellows’ Corner
An abstract is unavailable. This article is available as a PDF only.
- 22 April 2025
- Published by Wolters Kluwer Health in Liver Transplantation
- Vol. 31 (8) , 973-974
Fellows’ Corner
An abstract is unavailable. This article is available as a PDF only.
- 31 January 2025
- Published by Wolters Kluwer Health in Liver Transplantation
- Vol. 31 (7) , 849-850
From core to surface: Expanding the donor pool with HBsAg-positive liver allografts
An abstract is unavailable. This article is available as a PDF only.
- 31 January 2025
- Published by Wolters Kluwer Health in Liver Transplantation
- Vol. 31 (7) , 849-850
From core to surface: Expanding the donor pool with HBsAg-positive liver allografts
An abstract is unavailable. This article is available as a PDF only.
- 31 January 2025
- Published by Wolters Kluwer Health in Liver Transplantation
- Vol. 31 (5) , 561-562
Fellows’ Corner
An abstract is unavailable. This article is available as a PDF only.
- 31 January 2025
- Published by Wolters Kluwer Health in Liver Transplantation
- Vol. 31 (5) , 561-562
Fellows’ Corner
An abstract is unavailable. This article is available as a PDF only.
- 12 November 2024
- Published by Wolters Kluwer Health in Liver Transplantation
- Vol. 31 (2) , 129-130
Fellows’ Corner
- 12 November 2024
- Published by Wolters Kluwer Health in Liver Transplantation
- Vol. 31 (2) , 129-130
Fellows’ Corner
- 12 July 2024
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 120 (4) , 827-836
The Survival Benefit of Reabstinence After Harmful Alcohol Use Following Early Liver Transplant for Severe Alcohol-Associated Hepatitis: A Multicenter ACCELERATE Study
INTRODUCTION: Early (i.e., without mandated period of abstinence) liver transplant (LT) for alcohol-associated hepatitis is the fastest-growing indication for LT in the United States and Europe. Harmful alcohol use after LT is associated with poor outcomes, but the distinction of establishing abstinence after return to drinking (i.e., reabstinence) is understudied. This study aims to characterize the survival outcomes of achieving reabstinence after post-LT harmful alcohol use. METHODS: We analyzed early LT recipients from 12 US LT centers between 2006 and 2021. Post-LT alcohol use was characterized as harmful using criteria of “binge” (≥5 [men] or ≥4 [women] drinks in < 24 hours) or “frequent” (≥4 days in one week) by interview or phosphatidylethanol >20 ng/mL. Reabstinence was defined as ≥12 consecutive months without harmful alcohol use after harmful alcohol use. RESULTS: Among 347 LT recipients (64% male, median age 43, median Model for End-Stage Liver Disease-Sodium score 38) with median post-LT follow-up of 2.2 years (interquartile interval 1.1–3.6), 276 (80%) recipients had no evidence of harmful alcohol use, 35 (10%) recipients had reabstinence, and 36 (10%) recipients had continued harmful alcohol use without reabstinence. Five-year predicted survival, adjusted for age, sex, and Model for End-Stage Liver Disease-Sodium score, was lowest among LT recipients with continued harmful alcohol use (77%), but similar among those with no harmful use (93%) and reabstinence (94%). DISCUSSION: Achieving reabstinence after post-LT harmful alcohol use is associated with similar 5-year post-LT survival compared with those without evidence of post-LT harmful alcohol use. Our findings highlight the importance of early detection and treatment of post-LT alcohol use.
- 12 July 2024
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 120 (4) , 827-836
The Survival Benefit of Reabstinence After Harmful Alcohol Use Following Early Liver Transplant for Severe Alcohol-Associated Hepatitis: A Multicenter ACCELERATE Study
INTRODUCTION: Early (i.e., without mandated period of abstinence) liver transplant (LT) for alcohol-associated hepatitis is the fastest-growing indication for LT in the United States and Europe. Harmful alcohol use after LT is associated with poor outcomes, but the distinction of establishing abstinence after return to drinking (i.e., reabstinence) is understudied. This study aims to characterize the survival outcomes of achieving reabstinence after post-LT harmful alcohol use. METHODS: We analyzed early LT recipients from 12 US LT centers between 2006 and 2021. Post-LT alcohol use was characterized as harmful using criteria of “binge” (≥5 [men] or ≥4 [women] drinks in < 24 hours) or “frequent” (≥4 days in one week) by interview or phosphatidylethanol >20 ng/mL. Reabstinence was defined as ≥12 consecutive months without harmful alcohol use after harmful alcohol use. RESULTS: Among 347 LT recipients (64% male, median age 43, median Model for End-Stage Liver Disease-Sodium score 38) with median post-LT follow-up of 2.2 years (interquartile interval 1.1–3.6), 276 (80%) recipients had no evidence of harmful alcohol use, 35 (10%) recipients had reabstinence, and 36 (10%) recipients had continued harmful alcohol use without reabstinence. Five-year predicted survival, adjusted for age, sex, and Model for End-Stage Liver Disease-Sodium score, was lowest among LT recipients with continued harmful alcohol use (77%), but similar among those with no harmful use (93%) and reabstinence (94%). DISCUSSION: Achieving reabstinence after post-LT harmful alcohol use is associated with similar 5-year post-LT survival compared with those without evidence of post-LT harmful alcohol use. Our findings highlight the importance of early detection and treatment of post-LT alcohol use.